Gene editing with CRISPR used to treat lethal lung diseases in utero

Using CRISPR gene editing, researchers have thwarted a lethal lung disease, in an animal model, in which a harmful mutation causes death within hours after birth.

This proof-of-concept study, published in Science Translational Medicine, showed that in utero editing could be a promising new approach for treating lung diseases before birth.

“We wanted to know if this could work at all,” said study co-leader Edward E.  Morrisey, a professor of Cardiovascular Medicine and Cell and Developmental Biology in the Perelman School of Medicine at the University of Pennsylvania, and scientific director of Penn’s Institute for Regenerative Medicine.

“The trick was how to direct the gene-editing machinery to target cells that line the airways of the lungs.”

The lung conditions the team from Penn Medicine and Children’s Hospital of Philadelphia (CHOP) is hoping to solve — congenital diseases such as cystic fibrosis, surfactant protein deficiency, and alpha-1 antitrypsin — are characterised by respiratory failure at birth or chronic lung disease with few options for therapies.

About 22% of all paediatric hospital admissions are attributed to respiratory disorders, and congenital causes of respiratory diseases are often lethal, despite advances in care and a deeper understanding of their molecular causes.

Because the lung is a barrier organ in direct contact with the outside environment, targeted delivery to correct defective genes is an attractive therapy.

“The developing foetus has many innate properties that make it an attractive recipient for therapeutic gene editing,” said study co-leader William H. Peranteau, an investigator at CHOP’s Centre for Fatal Research, and a paediatric and fatal surgeon in CHOP’s Centre for Foetal Diagnosis and Treatment.

“The ability to cure or mitigate a disease via gene editing in mid- to late gestation before birth and the onset of irreversible pathology is very exciting.

“This is particularly true for diseases that affect the lungs, whose function becomes dramatically more important at the time of birth.”

The researchers showed that precisely timed in utero delivery of CRISPR gene-editing reagents to the amniotic fluid during foetal development resulted in targeted changes in the lungs of mice.

They introduced the gene editors into developing mice four days before birth, which is analogous to the third trimester in humans.

The cells that showed the highest percentage of editing were alveolar epithelial cells and airway secretory cells lining lung airways.

In 2018, a team led by Morrisey identified the alveolar epithelial progenitor (AEP) lineage, which is embedded in a larger population of cells called alveolar type 2 cells.

These cells generate pulmonary surfactant, which reduces surface tension in the lungs and keeps them from collapsing with every breath. AEPs are a stable cell type in the lung and turn over very slowly but replicate rapidly after injury to regenerate the lining of the alveoli and restore gas exchange.

In a second experiment, the researchers used prenatal gene-editing to reduce the severity of an interstitial lung disease called surfactant protein C (SFTPC) deficiency in a mouse model that has in common a disease-causing mutation found in the human Sftpc gene.

100% of untreated mice with this mutation die from respiratory failure within hours of birth. In contrast, prenatal gene-editing to inactivate the mutant Sftpc gene resulted in improved lung morphology and survival of over 22% of the animals.

Future studies will be directed towards increasing the efficiency of the gene editing in the epithelial lining of lungs as well as evaluating different mechanisms to deliver gene editing technology to lungs.

“Different gene editing techniques are also being explored that may one day be able to correct the exact mutations observed in genetic lung diseases in infants,” Morrisey said.

Morrisey collaborated on a recent study led by Peranteau and Kiran Musunuru, an associate professor of Cardiovascular Medicine at Penn, demonstrating the feasibility of in utero gene editing to rescue a lethal liver disease in a mouse model – the first time in utero CRISPR-mediated gene editing prevented a deadly metabolic disorder in animals.

Similar to that study, Peranteau said: “The current research is a proof-of-concept study highlighting the exciting future prospects for prenatal treatments including gene editing and replacement gene therapy for the treatment of congenital diseases.”

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...

Brilinta approved in US to reduce the risk of first heart attack or stroke

AstraZeneca’s Brilinta (ticagrelor) has been approved in the US to reduce the risk of a first heart attack or stroke in high-risk patients with...

GSK to manufacture 1bn doses of pandemic vaccine

GlaxoSmithKline (GSK) is aiming to manufacture one billion doses of its pandemic vaccine adjuvant system, in 2021, to support the development of multiple adjuvanted...

Related news

In brief: New head of R&D for Cellbox Solutions

Germany’s Cellbox Solutions has appointed Lonza Pharma and Biotech’s former Head of Biosolutions R&D as its new Head of R&D. Dr Herbert A. Mueller-Hartmann will...

Novavax selects PolyPeptide to manufacture critical component of COVID-19 vaccine

Novavax has selected CDMO PolyPeptide Group to manufacture a critical component of its novel coronavirus vaccine candidate, NVX-CoV2373. NVX-CoV2373 is a stable, prefusion protein made...

COVID-19 could hinder blockchain implementation in pharma supply chains

Even though blockchain stands out as a potential solution to improve pharma supply chains, COVID-19 may become a hindrance rather than a trigger in...

Emergent joins partnership for COVID-19 vaccine development & manufacturing

Emergent BioSolutions has been issued a task order under an existing contract with the Biomedical Advanced Research and Development Authority (BARDA) to deploy its...